Lancet Respiratory Medicine

Papers
(The H4-Index of Lancet Respiratory Medicine is 89. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Savolitinib in NSCLC: progress in the MET exon 14 journey934
Impact of Myanmar's earthquake on respiratory health587
FLiRTing with danger as SARS-CoV-2 variants evolve506
Predicted bodyweight—a misleading metric for tidal volume titration?475
Optimising trial design for cardiogenic shock: insights from the sixth Critical Care Clinical Trialists Workshop359
Top ten research priorities for breathlessness research: UK James Lind Alliance priority setting partnership297
Interstitial lung disease: a decade of progress and hope296
Predatory publishers appear in PubMed (and your inbox)280
First results from the international paediatric bronchiectasis registry (Child-BEAR-Net Registry) describing multicountry variations in childhood bronchiectasis and its management: a multicentre, cros251
Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials246
Thoracentesis: an old story and some new sources232
Risk factors for COVID-19-associated pulmonary aspergillosis: a systematic review and meta-analysis230
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial228
Why has the incidence of tuberculosis not reduced in London during the COVID-19 pandemic?209
Correction to Lancet Respir Med 2019; 7: 745–56203
GOLD report: 2022 update196
Concerns about PRISm192
The burden of tuberculosis in Libya184
Broad protection from SARS-CoV-2 variants without antigen matching183
Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis183
US Senate committee investigates asthma inhaler prices179
Major gaps in childhood pneumonia research priorities remain178
Rituximab for connective tissue disease-associated interstitial lung disease173
Australia bans engineered stone to prevent silicosis168
European Society of Intensive Care Medicine (ESICM) LIVES 35th Annual Congress168
Opioids bring peace to patients with IPF cough162
Correction to Lancet Respir Med 2024; 12: 129–40161
Chronic obstructive pulmonary disease: 10 years of precision-guided success161
Video laryngoscopy is not the nemesis of direct laryngoscopy160
European Respiratory Society International Congress 2022159
Eat or heat: fuel poverty and childhood respiratory health157
Concerns regarding a suggested long COVID paradigm – Authors' reply157
The course of action for effective anti-cytokine treatment in COVID-19154
Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study154
Postoperative CPAP after major abdominal surgery152
One-off low-dose CT for lung cancer screening in China: a multicentre, population-based, prospective cohort study149
Advancing precision medicine for acute respiratory distress syndrome146
Long COVID: systemic inflammation and obesity as therapeutic targets146
Overcoming barriers to scaling up tuberculosis preventive treatment for household contacts145
Challenges of modulating the risk of bronchopulmonary dysplasia in clinical trials145
Correction to Lancet Respir Med 2025; 13: 244–55142
Correction to Lancet Respir Med 2021; 9: 1275–87141
Patient with cystic fibrosis not diagnosed until age 23 years now treated with the new triple therapy Trikafta140
Transbronchial cryobiopsy followed by as-needed surgical lung biopsy versus immediate surgical lung biopsy for diagnosing interstitial lung disease (the COLD study): a randomised controlled trial137
Trump administration decimates worker health oversight136
Association of SARS-CoV-2 infection and persistence with long COVID135
Evaluation of the effect of multimorbidity on difficult-to-treat asthma using a novel score (MiDAS): a multinational study of asthma cohorts134
Chronic cough as a disease: implications for practice, research, and health care134
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing s133
Preoxygenation strategies for intubation of patients who are critically ill: a systematic review and network meta-analysis of randomised trials133
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial130
Perioperative lung expansion and pulmonary outcomes after open abdominal surgery versus usual care in the USA (PRIME-AIR): a multicentre, randomised, controlled, phase 3 trial130
Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial128
Health effects of gas fuels: interpreting evidence from a comprehensive meta-analysis127
Correction to Lancet Respir Med 2022; 10: 972–84126
Sarcoidosis and fatigue: there is a useful cognitive treatment? – Authors' reply126
Claudio Castanos—leader in cystic fibrosis care in Argentina125
Nasally delivered SARS-CoV-2 vaccines: future promise and challenges120
Nintedanib for treating progressive fibrosing interstitial lung diseases119
Priorities for NICE in health and social care119
Vaccination in the world's top athletes118
US EPA signals renewed regulatory scrutiny of toxic air pollution117
Genetic associations and lung function in IPF: unexpected answers, persistent questions114
Solid and semi-solid perspectives in thoracic surgery113
Awake prone positioning in COVID-19: is tummy time ready for prime time?112
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CRO112
Extracorporeal cardiopulmonary resuscitation: not why, but how112
Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis111
Improving lifelong respiratory health after preterm birth110
Endoscopic sinus surgery with medical therapy versus medical therapy for chronic rhinosinusitis with nasal polyps: a multicentre, randomised, controlled trial110
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, doub105
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis104
Lung epithelial and myeloid innate immunity in influenza-associated or COVID-19-associated pulmonary aspergillosis: an observational study104
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, co103
Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study101
Unveiling a hidden phenotype of early tuberculosis100
Health effects from climate-driven events: lessons learnt99
Azithromycin therapy for prevention of chronic lung disease of prematurity (AZTEC): a multicentre, double-blind, randomised, placebo-controlled trial98
Spirometry in female individuals – Authors' reply98
Choice overload for RSV prevention—how to form your opinion98
Pooled testing for TB: revisiting a cost-saving innovation97
Management after combined BPA and medical therapy in CTEPH: time for cardiopulmonary exercise testing96
Pre-COPD: an evolving concept with practice potential95
Unavailability of varenicline: a global tragedy for the fight against the tobacco epidemic95
Clean air, climate targets, and respiratory health in Europe94
Realignment of clinical research after the COVID-19 era94
Individualised, perioperative open-lung ventilation strategy during one-lung ventilation (iPROVE-OLV): a multicentre, randomised, controlled clinical trial94
Tackling tuberculosis: what lies beneath the surface?92
NICE guidance on nivolumab plus ipilimumab for untreated, unresectable malignant pleural mesothelioma90
Determinants of long-term outcomes in patients with COVID-19 supported with ECMO89
0.11410903930664